Modified NVs can simultaneously express antiPD-L1 antibodies (aPD-L1) and be a promising drug delivery vehicle for targeting PD-L1 ligand-overexpressed cancer cell and APCs [35–37]. This evidence concerns the gene CD274 and cancer.